Aequus Pharmaceuticals Inc (AQS.CA) Stock Price, Forecast & Analysis
Canada - TSX Venture Exchange - TSX-V:AQS - CA0076361033 - Common Stock
AQS.CA Key Statistics, Chart & Performance
The current stock price of AQS.CA is 0.005 CAD. In the past year, price decreased by -80%.
AQS.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| BHC.CA | BAUSCH HEALTH COS INC | 1.88 | 3.65B | ||
| TLRY.CA | TILRAY BRANDS INC | N/A | 1.61B | ||
| CRON.CA | CRONOS GROUP INC | 25.07 | 1.44B | ||
| DHT-UN.CA | DRI HEALTHCARE TRUST | 7.11 | 881.76M | ||
| WEED.CA | CANOPY GROWTH CORP | N/A | 655.86M | ||
| GUD.CA | KNIGHT THERAPEUTICS INC | N/A | 592.76M | ||
| NGEN.CA | NERVGEN PHARMA CORP | N/A | 528.16M | ||
| TSND.CA | TERRASCEND CORP | N/A | 405.08M | ||
| CPH.CA | CIPHER PHARMACEUTICALS INC | 16.78 | 383.09M | ||
| ACB.CA | AURORA CANNABIS INC | N/A | 352.50M | ||
| HITI.CA | HIGH TIDE INC | N/A | 339.40M | ||
| OGI.CA | ORGANIGRAM GLOBAL INC | N/A | 323.74M |
Related stock screener links
About AQS.CA
Company Profile
Aequus Pharmaceuticals, Inc. engages in the development and commercialization of alternatives to currently approved drugs. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2015-03-17. The firm is focused on developing and commercializing, differentiated products in ophthalmology. Its pipeline products include PAUL Glaucoma Implant, ZIMED PF, and REV-0100 / ReVision. PAUL is a glaucoma drainage device designed to regulate intraocular pressure in the patient’s eyes and prevent further progression of the disease. PAUL has introduced many design features and unified these into one device and offers a solution for patients with moderate to severe glaucoma. ZIMED PF is the first available multi-dose, preservative free, bimatoprost containing product in Canada. REV-0100 is in preclinical development as a treatment for Stargardt disease. REV-0100 works by reducing levels of a toxic lipid called lipid bisretinoid, which accumulates within the retina in material called lipofuscin.
Company Info
Aequus Pharmaceuticals Inc
Suite 2820, 200 Granville Street
Vancouver BRITISH COLUMBIA V6C 1S4 CA
CEO: Douglas Glen Janzen
Employees: 12
Phone: 16043367906
Aequus Pharmaceuticals Inc / AQS.CA FAQ
What does Aequus Pharmaceuticals Inc do?
Aequus Pharmaceuticals, Inc. engages in the development and commercialization of alternatives to currently approved drugs. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2015-03-17. The firm is focused on developing and commercializing, differentiated products in ophthalmology. Its pipeline products include PAUL Glaucoma Implant, ZIMED PF, and REV-0100 / ReVision. PAUL is a glaucoma drainage device designed to regulate intraocular pressure in the patient’s eyes and prevent further progression of the disease. PAUL has introduced many design features and unified these into one device and offers a solution for patients with moderate to severe glaucoma. ZIMED PF is the first available multi-dose, preservative free, bimatoprost containing product in Canada. REV-0100 is in preclinical development as a treatment for Stargardt disease. REV-0100 works by reducing levels of a toxic lipid called lipid bisretinoid, which accumulates within the retina in material called lipofuscin.
What is the current price of AQS stock?
The current stock price of AQS.CA is 0.005 CAD.
Does Aequus Pharmaceuticals Inc pay dividends?
AQS.CA does not pay a dividend.
What is the ChartMill technical and fundamental rating of AQS stock?
AQS.CA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Is Aequus Pharmaceuticals Inc (AQS.CA) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on AQS.CA.
Can you provide the number of employees for Aequus Pharmaceuticals Inc?
Aequus Pharmaceuticals Inc (AQS.CA) currently has 12 employees.
AQS.CA Technical Analysis
AQS.CA Financial Highlights
Over the last trailing twelve months AQS.CA reported a non-GAAP Earnings per Share(EPS) of -0.02. The EPS increased by 18.22% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -311.85% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |